Article By:
ChinaBio® Today
Saturday, August 11, 2018 7:27 PM EDT
Shanghai Junshi Biosciences has filed for a Hong Kong IPO that is expected to raise up to $500 million. Junshi is developing a pipeline of 13 biologic drugs, including immuno-oncology treatments.